| Code | Description | Claims | Beneficiaries | Total Paid |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
13,005 |
10,244 |
$1.10M |
| 80053 |
Comprehensive metabolic panel |
16,544 |
13,146 |
$1.07M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
9,487 |
7,077 |
$927K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,119 |
975 |
$652K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
4,195 |
3,597 |
$619K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,898 |
2,754 |
$490K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,278 |
1,150 |
$490K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
19,537 |
15,081 |
$323K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,998 |
1,777 |
$297K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
4,474 |
3,842 |
$253K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
6,171 |
4,796 |
$231K |
| 84484 |
|
4,749 |
3,325 |
$213K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,507 |
1,155 |
$178K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,128 |
1,585 |
$163K |
| 81001 |
|
7,294 |
6,199 |
$161K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
4,494 |
3,240 |
$155K |
| 84443 |
Thyroid stimulating hormone (TSH) |
4,730 |
4,377 |
$151K |
| 80061 |
Lipid panel |
4,692 |
4,423 |
$150K |
| 71046 |
Radiologic examination, chest; 2 views |
3,272 |
2,774 |
$146K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,200 |
2,626 |
$139K |
| 36415 |
Collection of venous blood by venipuncture |
14,020 |
11,669 |
$134K |
| 71045 |
Radiologic examination, chest; single view |
3,754 |
3,076 |
$125K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
4,928 |
3,841 |
$116K |
| 83605 |
|
3,572 |
2,684 |
$115K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
4,533 |
3,919 |
$105K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
2,077 |
1,963 |
$81K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
302 |
253 |
$79K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,358 |
3,129 |
$69K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
492 |
426 |
$66K |
| 83735 |
|
3,448 |
2,714 |
$65K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
928 |
853 |
$65K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,258 |
3,216 |
$64K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,364 |
907 |
$60K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
424 |
378 |
$59K |
| 87631 |
|
336 |
300 |
$59K |
| 87040 |
|
1,107 |
697 |
$58K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,441 |
3,565 |
$57K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,134 |
358 |
$55K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
806 |
723 |
$55K |
| 83690 |
|
2,938 |
2,429 |
$50K |
| 83880 |
|
1,211 |
942 |
$50K |
| 80305 |
|
923 |
804 |
$50K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
848 |
544 |
$49K |
| 96376 |
|
1,044 |
560 |
$48K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,907 |
1,711 |
$46K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,627 |
2,184 |
$43K |
| 71250 |
|
243 |
222 |
$42K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,937 |
1,695 |
$40K |
| 85610 |
|
2,826 |
2,306 |
$40K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,165 |
2,451 |
$40K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,482 |
3,077 |
$40K |
| 82803 |
|
1,018 |
760 |
$39K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
297 |
273 |
$38K |
| 82550 |
|
2,064 |
1,633 |
$36K |
| 87081 |
|
1,251 |
1,136 |
$33K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
136 |
124 |
$32K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
372 |
351 |
$31K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
629 |
520 |
$31K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
194 |
107 |
$30K |
| 97602 |
|
322 |
134 |
$30K |
| 29581 |
|
788 |
143 |
$28K |
| 85730 |
|
1,260 |
1,112 |
$27K |
| 84439 |
|
1,123 |
1,052 |
$22K |
| 85379 |
|
968 |
831 |
$22K |
| 96127 |
|
368 |
340 |
$21K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
372 |
351 |
$20K |
| 85027 |
|
1,336 |
1,112 |
$20K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
731 |
481 |
$19K |
| 81025 |
|
716 |
624 |
$17K |
| 94060 |
|
126 |
96 |
$17K |
| 90834 |
Psychotherapy, 45 minutes with patient |
188 |
146 |
$17K |
| 82248 |
|
2,016 |
1,814 |
$17K |
| 82607 |
|
527 |
495 |
$17K |
| 87077 |
|
1,016 |
918 |
$17K |
| G0378 |
Hospital observation service, per hour |
179 |
79 |
$17K |
| 82330 |
|
800 |
608 |
$15K |
| 87186 |
|
737 |
669 |
$15K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,373 |
1,157 |
$15K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
417 |
166 |
$15K |
| 85007 |
|
571 |
449 |
$15K |
| 82150 |
|
364 |
283 |
$15K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
326 |
292 |
$15K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
132 |
118 |
$14K |
| 36600 |
|
741 |
571 |
$14K |
| 90837 |
Psychotherapy, 53 minutes with patient |
106 |
77 |
$13K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,471 |
1,002 |
$13K |
| 73030 |
|
236 |
199 |
$12K |
| 97035 |
|
259 |
90 |
$12K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
145 |
124 |
$11K |
| 72110 |
|
122 |
118 |
$11K |
| 94760 |
|
481 |
226 |
$11K |
| 80050 |
General health panel |
85 |
84 |
$10K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
97 |
92 |
$10K |
| 73562 |
|
206 |
160 |
$10K |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
156 |
140 |
$10K |
| 73630 |
|
192 |
175 |
$9K |
| 73610 |
|
164 |
144 |
$9K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
48 |
39 |
$8K |
| 82805 |
|
317 |
237 |
$8K |
| 84100 |
|
164 |
147 |
$7K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
12 |
12 |
$6K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
525 |
372 |
$6K |
| 97014 |
|
143 |
62 |
$5K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
205 |
155 |
$5K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
559 |
449 |
$5K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
35 |
25 |
$5K |
| 82947 |
|
407 |
340 |
$5K |
| 85651 |
|
398 |
348 |
$4K |
| 84481 |
|
71 |
66 |
$4K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
85 |
27 |
$4K |
| 94729 |
|
154 |
109 |
$4K |
| 88142 |
|
182 |
170 |
$4K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
177 |
162 |
$4K |
| 84466 |
|
126 |
118 |
$4K |
| 97162 |
|
40 |
39 |
$4K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
44 |
39 |
$3K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
74 |
68 |
$3K |
| 94727 |
|
37 |
25 |
$3K |
| 73130 |
|
57 |
49 |
$3K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
14 |
12 |
$3K |
| 94726 |
|
61 |
40 |
$3K |
| 81002 |
|
496 |
464 |
$3K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
18 |
17 |
$2K |
| 73564 |
|
30 |
26 |
$2K |
| J3490 |
Unclassified drugs |
1,271 |
661 |
$2K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
300 |
184 |
$2K |
| 84520 |
|
163 |
129 |
$2K |
| 83540 |
|
155 |
142 |
$2K |
| 20610 |
|
54 |
27 |
$2K |
| 74018 |
|
28 |
28 |
$2K |
| 76536 |
|
15 |
14 |
$2K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
53 |
51 |
$2K |
| 11721 |
|
122 |
68 |
$2K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
442 |
371 |
$2K |
| J2704 |
Injection, propofol, 10 mg |
188 |
156 |
$2K |
| 90791 |
Psychiatric diagnostic evaluation |
16 |
15 |
$2K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
73 |
43 |
$2K |
| 87807 |
|
21 |
21 |
$1K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
15 |
13 |
$1K |
| 84132 |
|
187 |
143 |
$1K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
148 |
124 |
$1K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
102 |
82 |
$1K |
| 84295 |
|
170 |
131 |
$1K |
| 82435 |
|
170 |
131 |
$1K |
| 82565 |
|
35 |
29 |
$1K |
| 87147 |
|
32 |
29 |
$1K |
| 74019 |
|
19 |
12 |
$1K |
| 86140 |
|
153 |
117 |
$983.43 |
| 82570 |
|
108 |
104 |
$969.02 |
| 84145 |
|
153 |
100 |
$934.74 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
33 |
31 |
$899.37 |
| 96367 |
|
18 |
13 |
$887.72 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
287 |
225 |
$871.96 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
52 |
24 |
$861.04 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
19 |
12 |
$829.59 |
| 82728 |
|
24 |
24 |
$696.25 |
| 84460 |
|
14 |
13 |
$668.94 |
| 84450 |
|
14 |
13 |
$668.94 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
73 |
59 |
$634.24 |
| 80051 |
|
16 |
15 |
$623.65 |
| 82043 |
|
40 |
39 |
$498.66 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
91 |
83 |
$454.93 |
| 84703 |
|
30 |
28 |
$444.86 |
| G0475 |
Hiv antigen/antibody, combination assay, screening |
14 |
13 |
$426.38 |
| 84436 |
|
12 |
12 |
$360.57 |
| 80179 |
|
12 |
12 |
$342.09 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
63 |
38 |
$318.74 |
| 86850 |
|
27 |
24 |
$318.06 |
| 86803 |
|
13 |
12 |
$303.48 |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
49 |
38 |
$284.58 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
36 |
28 |
$247.20 |
| 87205 |
|
15 |
13 |
$181.84 |
| 86900 |
|
13 |
12 |
$134.30 |
| 85018 |
|
13 |
13 |
$133.82 |
| J2060 |
Injection, lorazepam, 2 mg |
44 |
36 |
$131.61 |
| 86901 |
|
13 |
12 |
$105.70 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
108 |
88 |
$48.61 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
53 |
39 |
$45.72 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
16 |
15 |
$44.19 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
45 |
40 |
$37.86 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
76 |
70 |
$14.82 |
| G1010 |
Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program |
27 |
25 |
$0.00 |